Amgen And The Institute For Protein Design At University Of Washington Announce Unique Strategic Research Partnership

安进与华盛顿大学达成战略协议,开展广泛合作以推动蛋白创新疗法研究

2019-06-20 17:36:00 PR Newswire

本文共1043个字,阅读需3分钟

Amgen (AMGN) and the University of Washington's Institute for Protein Design (IPD), which is revolutionizing its field of science by creating custom-designed proteins from scratch to improve human health, today announced a broad collaboration that will cover multiple projects with a goal of testing new technologies and creating protein-building approaches that can be broadly applied to the search for new medicines. Under the terms of the agreement, Amgen has provided initial funding for three sponsored research projects that will seek to apply IPD's de novo design technique to increase the versatility of traditional protein-based medicines. This will include optimizing Amgen's repertoire of BiTE® (bispecific T cell enager) antibodies, with the goal of expanding the types of tumors that can be targeted with these molecules. IPD's expertise could also help Amgen to generate antibodies against very challenging drug targets and to devise new ways to modulate the activity of the immune system. In the longer-term, the broad-based collaboration could help shape the discovery and development of protein-based therapies. "We're at a technology transition point from modifying what exists in nature, which has been the traditional approach to protein engineering, to using first principles to build proteins from scratch to have exactly the properties you want," said David Baker, the Henrietta and Aubrey Davis Endowed Professor of Biochemistry at the University of Washington School of Medicine, a Howard Hughes Medical Institute investigator, and the founder and director of IPD. "We can now design proteins that have specific functions, and that is where our work starts tying into medicine, and why we are very excited to be working with Amgen." "We want to work with IPD in an open-ended way to try to solve some of the most intractable problems that we face in designing effective medicines," said Raymond Deshaies, Ph.D., senior vice president of Global Research at Amgen. "This is a broad collaboration that will cover multiple projects, and we are hoping to build strong working relationships among scientists on both sides. The goal isn't just to solve a few specific problems but to create approaches that can be applied very generally across a large suite of problems." About the Institute for Protein DesignThe Institute for Protein Design, founded in 2012 at UW Medicine in Seattle, is a non-profit research center that creates custom-designed proteins to improve human health and address 21st-century challenges in energy, industry and technology. Proteins are essential molecules that perform vital functions inside every cell of the human body. Proteins also have applications outside the body, including as diagnostic tools, advanced nanomaterials, and more. The Institute's team of 140 faculty, staff, postdoctoral fellows and graduate students together work to design entirely novel proteins from scratch to create, for example, safer and more potent vaccines and therapeutics. The institute has assembled top experts in biochemistry, computer science, pharmacology, immunology and other basic sciences, as well as clinical medicine. In 2019, the Institute for Protein Design was selected as part of The Audacious Project, a successor to the TED Prize. For more information, visit www.ipd.uw.edu. About AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
安进(Amgen)( AMGN )和华盛顿大学蛋白质设计研究所( IPD )正在彻底改革其科学领域,从零开始创建定制设计的蛋白质,以改善人类健康,今天宣布了一项广泛的合作,将涵盖多个项目,目的是测试新技术和创建可广泛应用于寻找新药物的蛋白质构建方法。 根据协议条款,安进(Amgen)为三个赞助研究项目提供了初步资金,这些项目将寻求应用 IPD 的从头设计技术,以提高传统蛋白质药物的通用性。这将包括优化安进(Amgen)的 BiTE ®(双特异性 T 细胞启动子)抗体的配伍,目的是扩大肿瘤的类型,可以针对这些分子。IPD 的专业知识也可以帮助安进(Amgen)产生抗体对抗非常具有挑战性的药物目标,并设计新的方法来调节免疫系统的活动。从长远来看,广泛的合作可以帮助形成蛋白质疗法的发现和发展。 “我们正处于一个技术过渡阶段,从改变自然界中存在的东西,这一直是传统的蛋白质工程方法,到利用第一原则从头开始构建蛋白质,以完全拥有你想要的特性,” DavidBaker 说。Henrieta 和 Aubrey Davis 是华盛顿大学医学院生物化学教授,霍华德·休斯医学研究所研究员, IPD 创始人和主任。“我们现在可以设计具有特定功能的蛋白质,这就是我们的工作开始与医学结合的地方,也是为什么我们非常兴奋与安进(Amgen)合作的原因。” 安进(Amgen)全球研究高级副总裁 Raymond Deshaes 博士说:“我们希望与 IPD 合作,以一种开放的方式,试图解决一些我们在设计有效药物时所面临的最棘手的问题。”“这是一项广泛的合作,将涵盖多个项目,我们希望在双方科学家之间建立牢固的工作关系。我们的目标不仅仅是解决一些特定的问题,还包括创建一些方法,这些方法可以广泛地应用于一大组问题。” 蛋白质设计研究所蛋白质设计研究所成立于2012年,位于西雅图的华盛顿大学医学中心,是一个非营利性的研究中心,创造定制设计的蛋白质,以改善人类健康和解决21世纪的挑战,在能源,工业和技术。蛋白质是人体每个细胞中发挥重要功能的重要分子.蛋白质在人体外也有应用,包括诊断工具,先进的纳米材料等。该研究所由140名教员、工作人员、博士后研究员和研究生组成的团队,共同致力于从零开始设计全新的蛋白质,以创造出更安全、更有效的疫苗和疗法。该研究所汇集了生物化学、计算机科学、药理学、免疫学等基础科学以及临床医学的顶级专家。2019年,蛋白质设计研究所被选为大胆项目的一部分, TED 奖的继任者。

以上中文文本为机器翻译,存在不同程度偏差和错误,请理解并参考英文原文阅读。

阅读原文